Matson downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded Matson (MATX) to Peer Perform from Outperform. The firm cites valuation for the downgrade. Matson has materially ...
Hosted on MSN1d
Wolfe Research Downgrades Matson (MATX)
Fintel reports that on November 18, 2024, Wolfe Research downgraded their outlook for Matson (NYSE:MATX) from Outperform to ...
Fintel on MSN2d
Wolfe Research Initiates Coverage of Gilead Sciences (GILD) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...
bovnews8h
Why Did Wolfe Research Give Gilead Sciences, Inc. (GILD) Stock Outperform Rating?
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research
Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) to a strong-buy rating in a report ...
Wolfe Research starts Moderna at Underperform, sees limited upside opportunity
Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...
Amgen (NASDAQ:AMGN) Research Coverage Started at Wolfe Research
Wolfe Research started coverage on shares of Amgen (NASDAQ:AMGN – Free Report) in a report published on Friday, MarketBeat reports. The brokerage issued a peer perform rating on the medical research ...
bovnews10h
AbbVie Inc (ABBV) Stock: More Strategic Than Meets the Eye
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...
Investing3d
Wolfe Research sets stock target on Veracyte, cites growth potential
On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte ...
Seeking Alpha3d
U.S. Pharma is largely immune from 'MAHA' impact: Wolfe
Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic disease movement "Make America Healthy Again," championed by Robert F.
Nasdaq3d
Wolfe Research Initiates Coverage of AbbVie (SNSE:ABBVCL) with Outperform Recommendation
Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of AbbVie (SNSE:ABBVCL) with a Outperform recommendation. What is the Fund Sentiment? There are 4,922 funds or ...
Investing3d
Wolfe Research sets stock target on Veracyte, cites growth potential
On Friday, Wolfe Research initiated coverage on shares of Veracyte, Inc (NASDAQ:VCYT), a diagnostics company, with an Outperform rating and a price target of $50.00. The firm highlighted Veracyte's ...